Cognition Therapeutics to Present Findings on Potential Alzheimer’s Drug

Cognition Therapeutics (Nasdaq: CGTX) will present findings from studies of CT1812 for the treatment of adults with early, mild and moderate Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in late October 2023.

Prior topline results showed that CT1812 had a beneficial impact on synapse function with participants exhibiting fewer slow “theta” waves, which are associated with cognitive impairment, compared to placebo-treated participants. CT1812 also improved connectivity, which may indicate improved communication between different parts of the brain.

Anthony Caggiano, MD, Ph.D., Cognition’s CMO and head of R&D, said, “The approval of monoclonal antibody therapies against amyloid beta protofibrils represents an important milestone in Alzheimer’s drug development, but industry experts agree that combination treatments will likely be required to achieve greater impact on the disease. To this end, we and our colleagues at the National Institute of Aging and the Alzheimer’s Clinical Trials Consortium (ACTC) made the strategic decision to allow participants to enroll in the ongoing Phase 2 START study who are being administered lecanemab. We believe this will allow us to assess the benefit of CT1812 in real-world conditions.”

Highlights

CT1812 is an experimental, orally delivered, small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex.

CT1812 is currently in development for mild-to-moderate Alzheimer’s disease in the SHINE study (NCT03507790), early Alzheimer’s disease in the START study (NCT05531656), and dementia with Lewy bodies in the SHIMMER study (NCT05225415).

Cognition Therapeutics

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com.